At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Brolucizumab 3 mg/50 μL +1 moredrug
Likely dose
Brolucizumab 3 mg/50 μLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Brolucizumab 3 mg/50 μL and Brolucizumab 6 mg/50 μL for Neovascular Age-Related Macular Degeneration. Completed, enrolled 51 participants.
Detailed Summary
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of 3 intravitreal injections in subjects with neovascular age-related macular degeneration (AMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedJul 23, 2015
Enrollment StartAug 24, 2015
Primary CompletionSep 6, 2016
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.9 years ago
Interventions
Brolucizumab 3 mg/50 μLdrug
Administered as an intravitreal injection
Brolucizumab 6 mg/50 μLdrug
Administered as an intravitreal injection